How Barrett was paid
$4.1M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Elizabeth BarrettChief Executive Officer | $826,013 | $2,751,111 | — | $529,981 | $42,753 | $4,149,858 |
| Chris DegnanChief Financial Officer | $115,530 | $176,330 | $695,294 | $53,125 | $13,510 | $1,053,789 |
| Jason SmithGeneral Counsel and Chief Compliance Officer | $475,003 | $518,100 | — | $203,179 | $79,182 | $1,275,464 |
| Don KimFormer Chief Financial Officer | $363,694 | $376,800 | — | $623,728 | $1,364,222 | — |
What changed and why
- $4.15M$4.15M CEO total compensation in 2024, down from $4.64M in 2023.
- $2.75M$2.75M of the CEO’s 2024 compensation came from stock awards, including performance stock units.
- 87%87% of votes cast supported say-on-pay at the 2024 annual meeting.
- Performance stock units tied a substantial portion of executive equity to Zusduri’s first commercial sale.
- 20th percentile was the CEO’s 2024 total direct compensation position within the compensation peer group.
- 15th percentile was the non-CEO executives’ 2024 total direct compensation position within the compensation peer group.
Other UroGen Pharma proxy statements
- 2026 proxy statement
Elizabeth Barrett paid $4.3M (+4% on the year).
Filed Apr 30, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.